Trial Profile
A Phase 1, Randomized, Placebo- and Active-Controlled, 4-Period Crossover, Proof of Concept Glucose Clamp Study to Compare the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single Doses of TAK-329 With a Single Dose of a Subcutaneously-Injected Rapid-Acting Insulin Analog in Subjects With Type 1 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs TAK 329 (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- 10 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
- 10 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.